Salsalate

Source: Wikipedia, the free encyclopedia.
Salsalate
Clinical data
Trade namesDisalcid, Salflex
AHFS/Drugs.comMonograph
MedlinePlusa682880
ATC code
Legal status
Legal status
Identifiers
  • 2-(2-Hydroxybenzoyl)oxybenzoic acid
ECHA InfoCard
100.008.208 Edit this at Wikidata
Chemical and physical data
FormulaC14H10O5
Molar mass258.229 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Salsalate is a

(NSAID) classes.

Salsalate is the generic name of a prescription drug marketed under the brandnames Mono-Gesic, Salflex, Disalcid, and Salsitab. Other generic and brand name formulations may be available.[2]

Mechanism of action

Relative to other NSAIDs, salsalate has a weak inhibitory effect on the

TNF-alpha, and C-reactive protein.[3]

The mechanism through which salsalate is thought to reduce the production of these inflammatory chemical signals is through the inhibition of

blood sugar lowering properties.[4]

Medical uses

Salsalate may be used for inflammatory disorders such as rheumatoid arthritis or noninflammatory disorders such as osteoarthritis.[3][6]

Safety

The risk of

bleeding is a common concern with use of the NSAID class of medications. However, the bleeding risk associated with salsalate is lower than that associated with aspirin use.[4]

Research

Salsalate has been proposed for the prevention and treatment of type 2 diabetes mellitus due to its ability to lower insulin resistance associated with inflammation and may be useful in prediabetes.[3] However, the use of salsalate to prevent the progression from prediabetes to type 2 diabetes mellitus has received limited study.[3]

History

Salsalate had been suggested as possible treatment for diabetes as early as 1876.[3][7][8]

Synthesis

Salsalate synthesis:[9][10][11][12]

References

  1. FDA
    . Retrieved 22 Oct 2023.
  2. ^ "Salsalate". drugs.com.
  3. ^
    PMID 25126374
    .
  4. ^ .
  5. .
  6. .
  7. .
  8. ^ Ebstein W (1876). "Zur therapie des diabetes mellitus, insbesondere uber die anwendung des salicylsauren natron bei demselben". Berliner Klinische Wochenschrift. 13: 337–340.
  9. .
  10. .
  11. ^ DE 211403, "Verfarhen zur Darstellung einer kristallisierten Salicylosalicylsäure aus Salicylsäure oder ihrne Salzen [Process for preparing a crystallized salicylosalicylic acid from salicylic acid or its salts]", published 1909-06-25, assigned to C.F. Boehringer & Söhne 
  12. ^ DE 214044, "Verfarhen zur Darstellung einer kristallisierten Salicylosalicylsäure [Process for preparing a crystallized salicylosalicylic acid]", published 1909-09-20, assigned to C.F. Boehringer & Söhne